Cadmus Rich - Oct 28, 2021 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Medical Officer Head of R&D
Signature
/s/ Julie Feder
Stock symbol
AURA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
10/28/2021, 08:30 PM
Next filing
Nov 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AURA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 29.2K $5.21 Direct F1
holding AURA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 80.3K $2.74 Direct F2
holding AURA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 18.2K $3.15 Direct F3
holding AURA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 41.4K $4.25 Direct F4
holding AURA Stock Option (Right to Buy) Oct 28, 2021 Common Stock 126K $5.48 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option are fully vested as of October 23, 2021.
F2 The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of February 21, 2018 with the remainder vesting thereafter pro-rata in 36 monthly installments.
F3 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2019
F4 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2020
F5 The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021

Remarks:

Chief Medical Officer Head of R&D